100% of every donation goes directly to pancreatic cancer research.
Learn More

In The Fight Against Pancreatic Cancer, Knowledge is Power

After a pancreatic cancer diagnosis, every moment counts. By connecting patients with the latest research, Let’s Win is arming them with the facts! 

Newly Diagnosed 


Start here to learn about pancreatic cancer and available resources.

Finding Clinical Trials


 A clinical trial is a research study designed to evaluate a new cancer treatment. Patients enrolled in a clinical trial are among the first to receive new treatments before they become widely offered.

Latest News

Microsoft Finds Cancer Clues in Search Queries


Microsoft scientists have demonstrated that by analyzing large samples of search engine queries they may in some cases be able to identify internet users who are suffering from pancreatic cancer, even before they have received a diagnosis of the disease.

6.7.16
Read More >

ASCO Annual Meeting: Existing Treatments Used in New Ways - Mixing old and new chemotherapies to treat pancreatic cancer


Researchers found that adding capecitabine to standard treatment with gemcitabine helped patients live longer. Gemcitabine is the chemotherapy typically used to treat pancreatic cancer after surgery. Capecitabine is a chemotherapy most commonly used to treat breast and colorectal cancers. Adding capecitabine is a new approach to treating pancreatic cancer. Both gemcitabine and capecitabine are available as generic drugs.

6.3.16
Read More >

Chemotherapy Combination After Surgery Improves Survival in Pancreatic Cancer


Adding capecitabine to gemcitabine nearly doubled five-year overall survival (OS) rates compared with gemcitabine alone for patients with pancreatic cancer whose tumors had been surgically removed, as demonstrated in a Phase 3 European trial. The median overall survival (OS) was 28 months with the combination chemotherapy regimen compared to 25.5 months with gemcitabine alone, an improvement in survival of 18 percent.

6.3.16
Read More >

Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO


Results from a Phase 1 trial evaluating necuparanib, a novel drug, in combination with the standard of care, nab-paclitaxel (Abraxane) and gemcitabine, in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243), were presented last week at the 2016 ASCO annual meeting.

6.8.16
Read More >

ASCO 2016: Rucaparib Shows Clinical Benefit in BRCA-Mutated Pancreatic Cancer


The targeted PARP inhibitor rucaparib, which has demonstrated robust clinical activity in patients with ovarian cancer who have a BRCA mutation, also showed promise in previously treated patients with pancreatic cancer who have the mutation (about 9%), according to results from a Phase II clinical study presented at the 2016 ASCO Annual Meeting.

6.4.16
Read More >

96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort. Second study validates Immunovia´s IMMray™ PanCan-d test for early detection of pancreatic cancer


Using the proprietary IMMray™ technology platform and a biomarker signature, Immunovia’s blood test has been able to discriminate between pancreatic cancer patients with stage I, II, III, and IV has been derived from clinical studies covering about 2500 patient samples in two continents.

5.30.16
Read More >

Let's Win Launches!


The Lustgarten Foundation is proud to support the initiative Let's Win , the first-ever online community sharing new, innovative science-driven treatments for Pancreatic Cancer which launched this May!

5.16.16
Read More >

THE IMPROVISATIONAL ONCOLOGIST: In an era of rapidly proliferating, precisely targeted treatments, every cancer case has to be played by ear.


The Lustgarten Foundation’s Distinguished Scholar, Bert Vogelstein, M.D., a cancer geneticist at Johns Hopkins University, explains in the NY Times article his commitment to finding a treatment that can be effective and less expensive for several cancers, including pancreatic cancer. He discusses that despite our genetic diversity, targeting the 12 core pancreatic cancer pathways rather than the individual gene mutations involved in pancreatic cancer will ultimately impact how cancer is observed and treated.

5.12.16
Read More >

AACR Congratulates Newest National Academy of Sciences Members


The American Association for Cancer Research (AACR) congratulates its 10 members who have been elected to the National Academy of Sciences, including Hidde Ploegh, Ph.D., a Research Investigator and Kenneth Kinsler, Ph.D. (Early Detection Initiative) which have been elected are both Lustgarten Foundation grant recipients for their research in pancreatic cancer.

5.05.16
Read More >

Study Finds Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals


"As reported by Vasen et al in the Journal of Clinical Oncology, surveillance for pancreatic ductal adenocarcinoma in high-risk individuals appears to be of benefit in individuals at risk due to CDKN2A mutation, with the advantage being less clear among individuals at risk due to familial clustering of pancreatic cancer."

5.06.16
Read More >

10 Things Cancer Experts Do To Avoid Getting The Disease


There's really no way to soften this: About 1,685,210 cancer cases are expected to be diagnosed in 2016, according to the American Cancer Society, and almost 600,000 Americans will die from these dread diseases. But there are many things you can do to lower your chances of becoming a statistic. We asked top oncologists and other cancer specialists for advice.

4.21.16
Read More >

Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer


Promising research published in Nature demonstrates that there are four distinct subtypes of pancreatic cancer, and each has its own prognosis and molecular characteristics that may predict its responsiveness to certain therapies.

2.24.16
Read More >

BRCA Clinics Expand Further Beyond Breast Cancer - New thinking on pancreatic, prostate cancer treatment; centers consolidate patient care under one roof


“A clinic at University of California, San Francisco has set out to specifically treat patients with genetic mutations in BRCA1 and BRCA2, but not just for breast cancer. The mutations are widely recognized as inheritable causes of breast and ovarian cancers, but less well known for their roles in causing pancreatic, prostate and some other cancers that affect both men and women."

2.22.16
Read More >

12 Things You Must Know If Pancreatic Cancer Runs in Your Family


“One of our Research Investigators, Dr. Alison Klein (Johns Hopkins University) offers insight into how pancreatic cancer can run in families, and what to do to protect yourself."

1.26.16
Read More >

Pancreatic Cancer Ecosystem and Vitamin D


The Lustgarten Foundation's board member, Anne Glauber shares a personal journey as it relates to her own treatment of ‪#‎PancreaticCancer‬ with synthetic vitamin D and the micro-environment of the actual disease.

12.9.15
Read More >

Stand Up To Cancer, Cancer Research UK, and The Lustgarten Foundation Fund Team with $12 million


The Stand Up To Cancer – Cancer Research UK –Lustgarten Foundation Dream Team of top cancer researchers from the United States and the United Kingdom was named here today to launch a fresh attack on pancreatic cancer, one of the deadliest forms of cancer on both sides of the Atlantic.

11.6.15
Read More >

FDA Approves New Treatment for Advanced Pancreatic Cancer


The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

10.22.15
Read More >

Sharing Pancreatic Cancer Treatment Information - A Lifeline


The Lustgarten Foundation's board member, Anne Glauber shares her own treatment as a lifeline for other patients with ‪‎Pancreatic Cancer‬.

09.25.15
Read More >

Pancreatic Cancer Deserves Research Investment


In the battle against pancreatic cancer, every bit of medical progress is good news. This is one of the deadliest cancers of all.

08.16.15
Read More >

For the Most Lethal Cancer: Find the Best Science


The Lustgarten Foundations’ board member, Anne Glauber explains how living with pancreatic cancer has some blessings, creating a “life of love”, as well as meeting scientists and doctors committed to changing the course of this disease. “Although the past 40 years have given us very few (and no long-term) treatments for pancreatic cancer, there is now new progress from a number of exceptional scientists willing to focus on these challenges.”

07.31.15
Read More >

Naperville Pancreatic Cancer Research Walk


The 5th Annual Naperville Pancreatic Cancer Research Walk brought together a community of people joining the fight against the disease.In the past four years, this walk has raised over $166,000 for critically needed research. This year had the most walkers and donations to-date.

07.31.15
Read More >

Congress Must Pass 21st Century Cures Act Now


This is an incredibly exciting time in biomedical research[...]At a time of seemingly perennial gridlock in Washington, the U.S. Congress has emerged as a surprising catalyst for such change. A large bipartisan effort over the past year has identified ways to speed the availability of safe and more effective treatments for patients by taking full advantage of the latest science. That is what underpins the 21st Century Cures Act (HR 6) now making its way through Congress.

07.8.15
Read More >

Toward Blood-Based Cancer Detection


Dr. Bert Vogelstein, a Lustgarten Foundation Distinguished Scholar and the head of our Early Detection Initiative, is quoted in an article in The Scientist that highlights the future and hope of the “liquid biopsy”, or blood sample, as a means to detect cancer before clinical symptoms occur.

07.7.15
Read More >

Tiny Particles in Blood Useful for Early Diagnosis of Pancreatic Cancer


Dr. Raghu Kalluri, a Lustgarten Foundation-funded scientist at MD Anderson Cancer Center, has discovered that a protein called GPC1 is highly expressed on the surface of small, cancer-produced structures called “exosomes”. GPC1-expressing exosomes are released and detectable in the blood, which means they have the potential to become a clinical cancer biomarker.

06.24.15
Read More >

Study Identifies Multiple Genetic Changes Linked to Increased Pancreatic Cancer Risk


One of our own Research Investigators, Alison Klein at Johns Hopkins University School of Medicine, discovered four new genetic variations that may increase the risk for Pancreatic Cancer if it is present in a person's genome, or genetic blueprint.

06.23.15
Read More >

PEGPH20 Comibation Doubles PFS in HA-High Pancreatic Cancer


"Recent clinical work by one of our outstanding ‪grantees‬, Dr. Sunil Hingorani, has shown that, "the addition of the enzyme PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival (PFS) by 4.9 months compared with the two agents alone in untreated patients with advanced ‪pancreatic‬ ‪cancer‬ with high expression levels of hyaluronan (HA), according to interim findings from a phase II study presented at the 2015 ‪ASCO‬ Annual Meeting."

06.16.15
Read More >

Antibody Fragments Expand What PET Imaging Can 'See' In Mice


“Lustgarten-funded researchers Dr. Hidde Ploegh and Dr. Ralph Weissleder have designed a more sensitive and precise imaging technique to detect and monitor pancreatic tumors.

06.3.15
Read More >

Small Study Shows Genetic Biomarker May Predict Cancer Patients' Response to Immunotherapy Drug


Research findings published in the New England Journal of Medicine and funded in part by The Lustgarten Foundation show promise leveraging certain immunotherapy drugs for a small subset of pancreatic cancer patients where standard therapies have failed.

05.29.15
Read More >

Finding My Treatment For Pancreatic Cancer


The Lustgarten Foundation’s board member, Anne Glauber, explains the innovative treatment she is receiving for her stage IV pancreatic cancer.

05.15.15
Read More >

The Next Shock After a Pancreatic Cancer Diagnosis: Where Are the Treatments?


The Lustgarten Foundation's board member, Ann Glauber, is telling her story about being diagnosed with stage IV pancreatic cancer and her frustration with the lack of treatment options available.

05.11.15
Read More >

A Walk to Remember: Raising Awareness About Pancreatic Cancer


"Pancreatic cancer was something I knew little about until this "silent killer," as it is known, came into our lives with devastating speed and took someone we loved, so much, away, so quickly."

04.30.15
Read More >

Dr. Carl June offers pancreatic cancer patients revolutionary new immunotherapy


With a jointly funded $1.1 million grant provided by the Lustgarten Foundation and the Cancer Research Institute, scientists at the University of Pennsylvania will begin clinical testing of a new form of immunotheraopy, which they anticipate could dramatically improve patient health.

03.31.15
Read More >

2015 Ruth Leff Siegel Award


The pancreas Center is announcing a call for nominations for the third annual, 2015 Ruth Leff Siegel Award.

03.26.15
Read More >

$12 Million translational research grant announced


Cancer Research UK  and The Lustgarten Foundation join with SU2C to fund new Pancreatic Cancer Dream Team.

03.04.15
Read More >

New Clinical Trial


New immunotherapy clinical trial begins with support from SU2C and The Lustgarten Foundation Pancreatic Cancer Dream Team. 

02.10.15
Read More >

Lustgarten foundation Investigators


Multi million dollar grants allow scientists to dedicate more focus to identifying new breakthroughs in pancreatic cancer research and accelerating a path to a cure.  

02.06.15
Read More >

Cablevision's support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

2015 website development and design sponsored by Celgene

1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303